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Background: Rheumatoid arthritis (RA) increases the mortality and morbidity of cardiovascular disease
(CVD). However, the relationship between RA and the risk of CVD in the Japanese population remains
unclear.
Methods and results: This study comprised 571 RA patients who were admitted to Juntendo University
Hospital from January 1990 to December 2000. Cardiovascular events (CVEs) were deﬁned as cardiac
death, acute coronary syndrome (ACS), symptomatic stroke, and congestive heart failure. During follow-
up (mean 11.7±5.8 years), 7.5% of the patients died from all causes and 11.0% experienced CVEs. The
morbidity of stroke and ACS was 3.6 and 2.5 per 1000 person-years, respectively. The mean RA disease
duration at enrolment was signiﬁcantly longer in patients who experienced CVEs than in those who did
not experience CVEs (15.0±12.7 years vs. 10.8±9.7 years; p=0.01). Physical disabilities due to RA were
more severe in patients who experienced CVEs than in those who did not experience CVEs. Patients with
a long RA disease duration showed signiﬁcantly higher event rates (p=0.033). Cox proportional hazards
analysis identiﬁed a longer RA duration as an independent risk factor for CVD (hazard ratio 1.57, 95% CI
1.09–2.30, p=0.02).
Conclusion: Japanese RA patients showed a relatively high incidence of CVD, despite the fact that they
had few coronary risk factors. The RA disease duration was an independent risk factor for CVEs.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
Rheumatoid arthritis (RA) is a systemic inﬂammatory disease
hat affects approximately 0.3% of the Japanese population [1]. RA
eads to progressive joint deformity, long-term physical disability,
nd an increased risk of mortality from multiple comorbidities.
everal studies in Western populations have demonstrated that
ardiovascular disease (CVD) is related to the prognosis of RA
atients, although they had few traditional coronary risk factors
2–7]. CVD mortality in RA patients increased by as much as
0% compared with that in non-RA patients [8,9]. Another study
∗ Corresponding author at: 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
el.: +81 3 5802 1056; fax: +81 3 5689 0627.
E-mail address: tetsuro@juntendo.ac.jp (T. Miyazaki).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.018
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights rereported that RA patients were 60–70% more likely to die and
30–60% more likely to suffer a vascular event compared with
osteoarthritis patients and those with no arthritis [10]. RA has
recently been reported to be the cardiovascular risk equivalent of
diabetes in European countries [7,11].
However, the relationship of RA with long-term outcomes,
including cardiovascular events (CVEs), in the Japanese popula-
tion remains unclear. To elucidate the impacts of RA on CVEs, we
assessed the long-term prognosis in Japanese RA patients.
MethodsStudy population
This was a retrospective study investigating the long-term out-
comes of RA patients. We collected the medical records of 606
served.
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onsecutive patients admitted to Juntendo University Hospital
rom January1990 toDecember2000whohadbeendiagnosedwith
A. The reasons for hospitalization varied, with the most preva-
ent (37.3%) being the thorough examination of collagen diseases,
ncluding RA, and the next most prevalent was complications of
rthopedic diseases (23.5%). We evaluated the following patient
ata at enrolment: age, sex, present illness, past history, history of
moking, blood pressure (BP), body mass index (BMI), laboratory
ata, medications, and duration and severity of RA. To deter-
ine the severity of RA, we used Steinbrocker classiﬁcation, which
epicts the level of physical functional status in RA. We excluded
atients who had a history of malignancy, or those who were
iagnosed with juvenile idiopathic arthritis or adult Still’s disease.
regnant women were also excluded.
Finally, 571 patients were enrolled in this study. The tim-
ng of enrolment was the ﬁrst day of the hospitalization. Fasting
lood samples were collected from each admitted patient and
nalyzed for C-reactive protein (CRP), erythrocyte sedimentation
ate, rheumatoid factor, total cholesterol (TC), triglycerides (TG),
reatinine, and fasting glucose levels. Furthermore, an estimated
lomerular ﬁltration rate (eGFR) was calculated using serum cre-
tinine levels, age, and gender. This study was approved by the
nstitutional review board of Juntendo University Hospital.
eﬁnition of RA
A conﬁrmed diagnosis of RAwas based on the diagnostic criteria
dvocated by the American College of Rheumatology in 1987 [12].
eﬁnition of risk factors
Covariates were selected on the basis of their potential rela-
ionship with the incidence of either arthritis or CVD. BMI was
eﬁned as weight in kilograms divided by height in meters
quared. Hypertension (HT) was deﬁned as taking antihyper-
ensive drugs or having been diagnosed with HT in the past.
iabetes mellitus (DM) was deﬁned as taking appropriate med-
cations (insulin or oral hypoglycemic drugs) or having been
iagnosed with DM in the past. Smoking status was determined
y patient’s self-report. In addition, use of acetylsalicylic acid
ASA), a non-steroidal anti-inﬂammatory drug (NSAID), statins,
mmunosuppressants (i.e. methotrexate and mizoribine), or other
isease-modifying antirheumatic drugs (DMARDs; i.e. gold salts,
-penicillamine, actarit, and lobenzarit) were determined by eval-
ating all medications taken during the period of hospitalization.
his study population had not received newly developed bio-
ogical medicines (i.e. tumor necrosis factor-alpha inhibitors and
nterleukin-6 receptor-inhibiting monoclonal antibodies).
eﬁnition of incidence of CVEs
CVEs were deﬁned as cardiac death, acute coronary syndrome
ACS), symptomatic stroke, and congestive heart failure (CHF)
equiring hospitalization. ACSwas identiﬁed among acutemyocar-
ial infarction (AMI) or unstable angina (UAP) patients. AMI was
iagnosed based on the presence of typical chest pain with ST-
egment elevation on electrocardiogram and increased serum
reatine kinase levels. UAP was diagnosed according to Braun-
ald’s clinical classiﬁcation (Classes I, II, and III) [13]. UAP patients
howed characteristic chest pain symptoms associated with tran-
ient ischemic ST-segment shifts and normal serumcreatine kinase
evels. All ACS patients underwent coronary angiography that
emonstrated signiﬁcant stenosis in at least one major coronary
rtery [14]. Strokewasdeﬁned, according to theWorldHealthOrga-
ization criteria, as a focal neurological disorder with rapid onset
ersisting for at least 24h, or until death. This includes ischemiciology 64 (2014) 366–370 367
stroke and hemorrhagic stroke (intracerebral hemorrhage and sub-
arachnoid hemorrhage), and excludes transient ischemic attacks
(deﬁnedas focalneurological symptoms lasting less than24h), sub-
dural hemorrhage, epidural hemorrhage, poisoning, and symptoms
caused by trauma. Stroke diagnoses were veriﬁed by a neurol-
ogist [15]. Morbidity and mortality surveillance was conducted
by monitoring hospital records from Juntendo University Hospi-
tal. The medical records of all patients experiencing death and
patients experiencing selectedmorbidity outcomes, includingCVD,
were evaluated. The follow-up duration was calculated as the time
between enrolment and a fatal or non-fatal CVE, death, or date of
last visit, whichever came ﬁrst until December 2010.
Statistical analyses
Continuous variables are expressed as mean± standard devi-
ation (SD) and were compared using Student’s t-test. Categorical
datawere tabulated as frequencies and percentages, and compared
using the chi-square test or Fisher’s exact test. The Kaplan–Meier
estimation with a log-rank test was used for unadjusted analysis.
We calculated the hazard ratio (HR) with 95% conﬁdence intervals
(CIs) for each endpoint of each subgroup relative to the refer-
ence category, using the multivariate Cox proportional hazards
model with adjustments for age, gender, BMI, BP, TC, creatinine
and glucose levels, Steinbrocker classiﬁcation, and duration of RA.
Logistic regression analysis was adjusted for multiple potential
confounders (age, gender, mean BP, BMI, CRP, TC, creatinine and
glucose levels, andmedical treatment). A p-value of <0.05was con-
sidered signiﬁcant. All data were analyzed using JMP software (SAS
Institute, Cary, NC, USA).
Results
Baseline characteristics and coronary risk factors
The baseline characteristics of the patients in this study are
shown in Table 1. The prevalence of classical coronary risk factors
was relatively low in this population. Most patients were women,
non-obese, and had normal BP. In addition, most patients had nor-
mal levels of TC, TG, fasting glucose, and eGFR. However, the levels
of several inﬂammatory markers were high, indicating the pres-
ence of inﬂammation from RA. As for medication, 397 patients had
steroids, 38 had ASA, 35 had statins, 92 had immunosuppressants,
and 267 had other DMARDs.
Analysis for mortality and CVEs
The mean follow-up period was 11.7±5.8 years. During this
period, 43 patients (7.5%) died from all causes and 63 patients
(11.0%) experienced CVEs (Table 2). Themorbidity of strokewas 3.6
per 1000 person-years and that of ACS was 2.5 per 1000 person-
years.
In addition, we examined differences in characteristics between
patients who experienced CVEs and those who did not (the CVE
and non-CVE groups). As shown in Table 3, patients in the CVE
group were signiﬁcantly older, more likely to be men, and more
likely to have HT, DM, and a past history of CVD. Thus, there were
more ASA users in the CVE group at baseline. There were no sig-
niﬁcant differences in steroid use or the mean dose of steroids
converted to the equivalent dose of prednisolone (8.4±6.1mg/dl
vs. 8.1±7.5mg/dl), between patients in the CVE group and patients
in the non-CVE group. According to laboratory data, patients in the
CVE group had signiﬁcantly lower eGFRs than those in the non-CVE
group. TG levels were signiﬁcantly higher in patients in the CVE
group than that in the non-CVE group. TC, glucose levels, and levels
of inﬂammatory markers did not differ between the two groups.
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Table 1
Baseline characteristics of patients with and without a history of cardiovascular
events.
n=571
Age (years) 58±13
Male (%) 95 (16.6)
BMI (kg/m2) 21.2±4.1
Current smoker (%) 91 (15.9)
DM (%) 56 (9.8)
Hypertension (%) 93 (16.3)
Systolic BP (mmHg) 126±20
Diastolic BP (mmHg) 72±13
Past history of CHD 37(6.5%)
Duration of RA (years) 11.3±10.2
Steinbrocker classiﬁcation 2.2±0.8
Total cholesterol (mg/dl) 183±45
Triglyceride (mg/dl) 114±53
Glucose (mg/dl) 96±28
Creatinine (mg/dl) 0.75±0.78
eGFR (ml/min/1.73m2) 104±45
CRP (mg/dl) 2.9±3.4
ESR (mm/h) 52.3±40.7
Rheumatoid factor (U/ml) 265±808
Medications
Steroids (%) 397 (70.3)
ASA (%) 38 (6.7)
Statins (%) 35 (6.6)
Immunosuppressants (%) 92 (16.1)
Other DMARDs (%) 267 (46.8)
CHD, coronaryheart disease; BMI, bodymass index;DM,diabetesmellitus; BP, blood
pressure; eGFR, estimated glomerular ﬁltration rate; RA, rheumatoid arthritis; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; ASA, acetylsalicylic acid;
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Table 3
Comparison of characteristics of patients with or without cardiovascular events
(CVEs).
CVE (+) (n=63) CVE (−) (n=508) p
Age (years) 61±9 58±13 0.009
Male (%) 20 (31.7) 75 (14.7) 0.002
BMI (kg/m2) 21.5±4.6 21.1±4.0 NS
Current smoker (%) 13 (20.6) 78 (15.3) NS
Past history of CHD (%) 10 (15.9) 27 (5.3) 0.033
DM (%) 11 (17.5) 45 (8.9) 0.041
Hypertension (%) 24 (38.0) 69 (13.6) <0.001
Systolic BP (mmHg) 131±22 125±20 0.044
Diastolic BP (mmHg) 74±16 71±12 NS
Duration of RA (years) 15.0±12.7 10.8±9.7 0.013
Steinbrocker classiﬁcation 2.3±0.8 2.2±0.8 NS
Steinbrocker Class 3 or 4 20 (31.7) 111 (21.9) 0.082
TC (mg/dl) 186±47 182±45 NS
Triglyceride (mg/dl) 133±66 112±51 0.031
Glucose (mg/dl) 99±32 95±28 NS
Creatinine (mg/dl) 1.01±1.12 0.72±0.73 0.057
eGFR (ml/min/1.73m2) 68.9±29.7 84.6±31.2 <0.001
CRP (mg/dl) 2.62±3.06 2.98±3.48 NS
ESR (mm/h) 51.1±33.9 52.5±41.5 NS
Rheumatoid factor (U/ml) 202±371 272±847 NS
Medications
Steroids (%) 41 (65.0) 360 (70.9) NS
ASA (%) 10 (15.9) 28 (5.5) 0.005
Statins (%) 6 (9.5) 29 (5.7) NS
Immunosuppressants (%) 9 (14.3) 83 (16.3) NS
Other DMARDs (%) 23 (36.5) 244 (48.0) NS
CHD, coronary heart disease; BMI, body mass index; DM, diabetes mellitus; BP,
blood pressure; TC, total cholesterol; eGFR, estimated glomerular ﬁltration rate;MARDs, disease-modifying antirheumatic drugs. Class indicates the Steinbrocker
lassiﬁcation, which shows the level of physical functional status in RA.
Focusing on RA, the mean disease duration of RA at enrolment
as signiﬁcantly longer in the CVE group. Moreover, Steinbrocker
unctional classiﬁcations were relatively worse in the CVE group.
e comparedpatientswithmildphysical disability (mildRAgroup,
eﬁned as Steinbrocker classiﬁcation 1 or 2) and those with severe
hysical disability (severeRAgroup, deﬁnedas class3or4). TheCVE
roup tended to consist of severe RA patients.We divided the study
atients into tertiles based on RA disease duration at enrolment.
ean RA duration in each group (the short, moderate, and long
roups) was 1.4±1.5 years, 9.2±2.6 years, and 22.6±8.2 years,
espectively. In our study population, signiﬁcantly higher event
ates occurred in patients who had a longer RA duration compared
ith patients in the ﬁrst tertile of RA duration (Fig. 1A). Further-
ore, severe physical disability due to RA was associated with an
ncrease in CVE comorbidity, but this association was not signiﬁ-
ant (Fig. 1B). Cox proportional hazards analysis identiﬁed longer
able 2
ummary of cardiovascular events and deaths.
N
All-cause death (%) 43 (7.5)
Cardiovascular death (%) 8 (1.4)
Coronary heart diseases 3
Stroke 0
Cardiac sudden death 2
Congestive heart failure 3
Cancer (%) 8 (1.4)
Infectious disease (%) 14 (2.5)
Gastrointestinal disease (%) 2 (0.4)
Respiratory disease (%) 11 (1.9)
Non-fatal cardiovascular events (%) 55 (9.6)
Acute coronary syndrome (%) 17 (3.9)
Symptomatic stroke (%) 24 (4.2)
Admission for heart failure (%) 14 (2.4)RA, rheumatoid arthritis; CRP, C-reactive protein; ESR, erythrocyte sedimentation
rate; ASA, acetylsalicylic acid; DMARDs, disease-modifying antirheumatic drugs.
RA duration at enrolment as an independent risk factor for CVEs
(HR 1.57, 95% CI 1.09–2.30, p=0.02) (Table 4) after adjustment for
age, gender, mean BP, BMI, CRP, TC, creatinine and glucose lev-
els, and past history of CHD. In addition, longer RA duration at
enrolment was still an independent risk factor for CVE after adjust-
ment for these confounding factors and usage of steroids, ASA,
statins, immunosuppressants, and other DMARDs (HR 1.48, 95% CI
1.01–2.21, p=0.04).
Discussion
To the best of our knowledge, this study is the ﬁrst to perform
a long-term evaluation of CVEs in Japanese RA patients. Japanese
RA patients have a potential risk for CVD, despite the fact that they
have few traditional cardiovascular risk factors. In addition, both
RA duration and physical disability were associated with future
CVEs. In particular, a longer RA duration was determined to be an
independent risk factor for the development of CVDs.
In the Japan Lipid Intervention Trial (J-LIT), myocardial infarc-
tionmorbidity in the primary prevention cohort was 0.87 per 1000
person-years (with AP, 1.51 per 1000 person-years) and that in
the secondary prevention cohort was 4.24 per 1000 person-years
[16,17]. In our study population, strokemorbiditywas 3.6 per 1000
person-years and ACS morbidity was 2.5 per 1000 person-years,
although RA patients had few traditional coronary risk factors.
According to the Japanese Atherosclerosis Society (JAS) Guidelines
for Prevention of Atherosclerosis Cardiovascular Disease 2012, the
10-year risk of CHDdeath in Japanese subjectswhohave equivalent
risk factors shown in this RA population is less than 0.5% [18]. NIP-
PON DATA 80 also demonstrated that stroke morbidity was 0.3 per
1000 person-years and CHD morbidity was 0.1 per 1000 person-
years in both Japanese men and women who had equivalent risk
factors [19]. Because the deﬁnition of CVEs in these studies differ
from ours, it is difﬁcult to compare results directly; however, CVE
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Follow-up (years)
Class 1+2               294                276               272               265                265
Class 3+4  131                118               113                111               111
P=0.07
Class 1+2
Class 3+4
Long
Short
Middle
Short (1.4±1.5) 186 177 174               173                173
Middle (9.2±2.6) 188 179 174               168                168
Long (22.6±8.2) 197 178 170               168                167
A
B
P=0.033
Duraon of RA at enrolment (years)
Severity of RA
Fig. 1. (A) Signiﬁcantly higher event rates were observed in rheumatoid arthritis
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HRA) patients with a longer disease duration (log-rank test: p=0.048). (B) Patients
ith severe physical disability due to RA tended to show higher event rates than
hose with mild physical disability (log-rank test: p=0.10).
orbidity in our patients appeared to be higher, at least, than that
f the healthy Japanese population.
A longer RA duration at enrolment was signiﬁcantly associated
ith CVEs in our study population. Long RA duration correlated
ith the risk of CVD, including coronary artery calciﬁcation and
arotid artery intima-media thickness [20,21]. The presence of
nﬂammationmaypotentially explain the increasedCVDmorbidity
nRApatients. Several inﬂammatorymarkers linked toCVD, includ-
ng CRP, ﬁbrinogen, and soluble intercellular adhesion molecule-1,
re elevated in RA patients [1,3]. These inﬂammatory cytokines,
long with prothrombotic and adhesion molecules, may mediate a
redisposition to vascular damage in RA. In an inﬂammatory state,
able 4
ultivariate Cox proportional hazards regression analysis for cardiovascular events.
Univariate
HR 95% CI p
Age (years) 2.51 1.00–1.04 0
Male 2.51 1.45–4.22 0
BMI (kg/m2) 1.02 0.96–1.07 N
Mean BP (mmHg) 1.02 1.00–1.04 0
TC (mg/dl) 1.00 0.99–1.01 N
Creatinine (mg/dl) 1.23 1.02–1.40 0
Glucose (mg/dl) 1.00 0.99–1.01 N
Past history of CHD 3.41 1.63–6.40 0
RA duration 1.51 1.11–2.09 0
R, hazard ratio; CI, conﬁdence interval; BMI, body mass index; BP, blood pressure; TC, toiology 64 (2014) 366–370 369
endothelial cell activation, vascular dysfunction, and subsequent
atherosclerosis can develop [22–25]. Moreover, methotrexate, a
potent immunosuppressant, has been shown to improve the prog-
nosis of RApatients by reducingCVDmortality [26]. Tumornecrosis
factor-alpha inhibitors may alter the CVD risk of RA patients by
increasing high-density lipoprotein cholesterol and adiponectin,
improving insulin resistance, and reducing CRP [27–29]. Although
CRP levels did not differ between the CVE and non-CVE groups,
their mean CRP levels were higher than upper limit of normal, and
the CVE group showed longer disease duration of RA. Therefore, we
speculate that continuous inﬂammation may affect the incidence
of CVE in this population. Another explanation is an adverse effect
of the medical treatment. In particular, long-term use of steroids
may induce atherosclerosis [30], although steroid treatment did
not differ between the CVE and non-CVE groups in our study.
The progression of physical disability was also related to the
incidence of CVE. Improvement in functional status with higher
physical activity may be associated with a decline in AMI mortal-
ity in RA patients [31]. The advanced damage of joints in RA has
led to the notion that RA patients should rest because exercise
mayenhance jointdamage.However, several studieshaveprovided
substantial evidence that exercise inhibits disease progression and
improves both the well-being and functional ability of RA patients
[32]. Physical activity is closely linked to inﬂammation, which is
an independent risk factor for CVEs [33–36]. In this study popu-
lation, the CVE group tended to consist of severe RA patients as
assessed by Steinbrocker classiﬁcation, which depicts the level of
physical functional status in RA. Thus, maintaining physical activ-
ity in RA patients may be important to prevent the occurrence of
future CVEs.
Study limitations
Our study was retrospective, based only on medical records
from the Juntendo University Hospital. It is possible that some
eventsmayhavebeen lost. Therefore,wemayhaveunderestimated
the real incidence of CVE. Even if this is taken into consideration,
our study showed a relative high incidence of CVEs in Japanese
RA patients. In addition, this study has no suitable controls to
evaluate the incidence rate of CVE in the Japanese RA popula-
tion. To establish a deﬁnite relationship between RA and CVD, a
cohort study should be conducted in Japan, as inWestern countries.
Furthermore, since we enrolled patients admitted to our hospital
from 1990 to 2000, this study population had not received newly
developed biological medicines (i.e. tumor necrosis factor-alpha
inhibitors and interleukin-6 receptor-inhibiting monoclonal anti-
bodies), which have anti-inﬂammatory effects. Therefore, further
prospective studies are warranted to elucidate the effects of these
biological medicines on the development of CVD in Japanese RA
patients.
Multivariate
HR 95% CI p
.03 1.01 0.98–1.03 NS
.001 1.94 0.94–3.43 NS
S 0.99 0.98–1.03 NS
.02 1.01 0.99–1.03 NS
S 1.00 0.99–1.01 NS
.04 1.35 1.04–1.63 0.02
S 1.00 0.99–1.01 NS
.002 2.85 1.26–5.82 0.01
.009 1.57 1.09–2.30 0.02
tal cholesterol; CHD, coronary heart disease; RA, rheumatoid arthritis.
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